Skip to main content
SpringerLink
Log in

Glycopeptides, Lipopeptides, and Lipoglycopeptides

  • Chapter
  • First Online:
Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions

Part of the book series: Infectious Disease ((ID))

  • 914 Accesses

Abstract

With increasing resistance in gram-positive organisms, the use of glycopeptides, lipopeptides, and lipoglycopeptides increases. These three classes of drugs are primarily renally eliminated; therefore, CYP450 interactions are not of concern. Daptomycin, the only agent in the class of lipopeptides, should be closely monitored with other drugs that are likely to cause muscle damage, especially HMG-CoA reductase inhibitors, due to adverse events related to increases in creatine phosphokinase levels, a marker of muscle injury. The newest class, lipoglycopeptides, includes three agents: telavancin, oritavancin, and dalbavancin. Of these, only telavancin is known to affect the QTc interval and should be used cautiously with other agents known to have similar effects. Drug interactions with the glycopeptide, vancomycin, are likely to involve other renally eliminated drugs; renal function should be closely monitored when vancomycin, daptomycin, or telavancin is prescribed concurrently with other nephrotoxic agents. As lipoglycopeptides increase, more information regarding possible drug interactions will be available to clinicians.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Guskey MT, Tsuji BT (2010) A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 30:80–94

    Article  CAS  PubMed  Google Scholar 

  2. (2017) Cubicin (daptomycin) product information. Cubist Pharmaceuticals, Inc, Lexington

    Google Scholar 

  3. (2016) Vibativ (telavancin) product information. Theravance, Inc., South San Francisco

    Google Scholar 

  4. (2017) Vancomycin product information. Hospira, Inc., Lake Forest

    Google Scholar 

  5. (2016) Dalvance (dalbavancin) product information. Durata Therapeutics US Ltd, Parsippany

    Google Scholar 

  6. (2016) Orbactiv (oritavancin) product information. The Medicines Company, Parsippany

    Google Scholar 

  7. Rybak M, Lomaestro B, Rotschafer JC et al (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82–98

    Article  CAS  PubMed  Google Scholar 

  8. (2011) Vancocin (vancomycin) product information. Viro Pharma Incorporated, Exton

    Google Scholar 

  9. Cohen SH, Gerding DN, Johnson S et al (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:431–455

    Article  PubMed  Google Scholar 

  10. Gerding DN, Muto CA, Owens RC Jr (2008) Treatment of Clostridium difficile infection. Clin Infect Dis 46(Suppl 1):S32–S42

    Article  CAS  PubMed  Google Scholar 

  11. Dudley MN, Quintiliani R, Nightingale CH, Gontarz N (1984) Absorption of vancomycin. Ann Intern Med 101:144

    Article  CAS  PubMed  Google Scholar 

  12. Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG (1978) Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 2:226–228

    Article  CAS  PubMed  Google Scholar 

  13. Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A (1999) Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 25:1100–1104

    Article  CAS  PubMed  Google Scholar 

  14. Somerville AL, Wright DH, Rotschafer JC (1999) Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 19:702–707

    Article  CAS  PubMed  Google Scholar 

  15. Cunha BA, Eisenstein LE, Hamid NS (2006) Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged/high-dose daptomycin without toxicity. Heart Lung 35:207–211

    Article  PubMed  Google Scholar 

  16. Cunha BA, Krol V, Kodali V (2008) Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 37:72–75

    Article  PubMed  Google Scholar 

  17. Cunha BA, Mickail N, Eisenstein L (2007) E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 36:456–461

    Article  PubMed  Google Scholar 

  18. Figueroa DA, Mangini E, Amodio-Groton M et al (2009) Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 49:177–180

    Article  CAS  PubMed  Google Scholar 

  19. Katz DE, Lindfield KC, Steenbergen JN et al (2008) A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 62:1455–1464

    Article  CAS  PubMed  Google Scholar 

  20. Lichterfeld M, Ferraro MJ, Davis BT (2010) High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. Int J Antimicrob Agents 35:96

    Article  CAS  PubMed  Google Scholar 

  21. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC (2009) Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy. Ann Pharmacother 43:1211–1219

    Article  CAS  PubMed  Google Scholar 

  22. Lubbert C, Rodloff AC, Hamed K (2015) Real-world treatment of enterococcal infections with daptomycin: insights from a large european registry (EU-CORE). Infect Dise Ther 4:259–271

    Article  Google Scholar 

  23. Oleson FB, Berman CL, Li AP (2004) An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 150:137–147

    Article  CAS  PubMed  Google Scholar 

  24. Steenbergen JN, Mohr JF, Thorne GM (2009) Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies. J Antimicrob Chemother 64:1130–1138

    Article  CAS  PubMed  Google Scholar 

  25. Odero RO, Cleveland KO, Gelfand MS (2009) Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J Antimicrob Chemother 63:1299–1300

    Article  CAS  PubMed  Google Scholar 

  26. Schriever CA, Fernandez C, Rodvold KA, Danziger LH (2005) Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62:1145–1158

    CAS  PubMed  Google Scholar 

  27. Stein GE (2005) Safety of newer parenteral antibiotics. Clin Infect Dis 41(Suppl 5):S293–S302

    Article  CAS  PubMed  Google Scholar 

  28. Chakraborty A, Roy S, Loeffler J, Chaves RL (2009) Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother 64:151–158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Saravolatz LD, Stein GE, Johnson LB (2009) Telavancin: a novel lipoglycopeptide. Clin Infect Dis 49:1908–1914

    Article  CAS  PubMed  Google Scholar 

  30. Stucki A, Gerber P, Acosta F, Cottagnoud M, Cottagnoud P (2006) Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother 50:770–773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gander S, Kinnaird A, Finch R (2005) Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 56:337–343

    Article  CAS  PubMed  Google Scholar 

  32. LaPlante KL, Mermel LA (2009) In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob Agents Chemother 53:3166–3169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL (2010) Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy 30:136–143

    Article  CAS  PubMed  Google Scholar 

  34. (2009) Vfend (voriconazole) product information. Pfizer, New York

    Google Scholar 

  35. Stryjewski ME, Chu VH, O'Riordan WD et al (2006) Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50:862–867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Stryjewski ME, Graham DR, Wilson SE et al (2008) Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46:1683–1693

    Article  CAS  PubMed  Google Scholar 

  37. Stryjewski ME, O'Riordan WD, Lau WK et al (2005) Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 40:1601–1607

    Article  CAS  PubMed  Google Scholar 

  38. Barriere S, Genter F, Spencer E et al (2004) Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 44:689–695

    Article  CAS  PubMed  Google Scholar 

  39. Corey GR, Kabler H, Mehra P et al (2014) Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med 370:2180–2190

    Article  PubMed  Google Scholar 

  40. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ (1987) Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 83:1091–1097

    Article  CAS  PubMed  Google Scholar 

  41. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH (1990) Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 25:679–687

    Article  CAS  PubMed  Google Scholar 

  42. Cosgrove SE, Vigliani GA, Fowler VG Jr et al (2009) Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48:713–721

    Article  PubMed  Google Scholar 

  43. Nishimura RA, Carabello BA, Faxon DP et al (2008) ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 52:676–685

    Article  PubMed  Google Scholar 

  44. Spivey JM, Gal P (1986) Vancomycin pharmacokinetics in neonates. Am J Dis Child 140:859

    CAS  PubMed  Google Scholar 

  45. Huang KC, Heise A, Shrader AK, Tsueda K (1990) Vancomycin enhances the neuromuscular blockade of vecuronium. Anesth Analg 71:194–196

    Article  CAS  PubMed  Google Scholar 

  46. Barg NL, Supena RB, Fekety R (1986) Persistent staphylococcal bacteremia in an intravenous drug abuser. Antimicrob Agents Chemother 29:209–211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Giuliano CA, Patel CR, Kale-Pradhan PB (2016) Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis. Pharmacothyerapy 36:1271–1228

    Google Scholar 

  48. Taylor NS, Bartlett JG (1980) Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis 141:92–97

    Article  CAS  PubMed  Google Scholar 

  49. Chatzizisis YS, Koskinas KC, Misirli G et al (2010) Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 33:171–187

    Article  CAS  PubMed  Google Scholar 

  50. Beauchamp D, Pellerin M, Gourde P, Pettigrew M, Bergeron MG (1990) Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob Agents Chemother 34:139–147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Couture M, Simard M, Gourde P et al (1994) Daptomycin may attenuate experimental tobramycin nephrotoxicity by electrostatic complexation to tobramycin. Antimicrob Agents Chemother 38:742–749

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Miro JM, Garcia-de-la-Maria C, Armero Y et al (2009) Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53:4172–4177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. van den Besselaar AMHP, Tripodi A (2007) Effect of daptomycin on prothrombin time and the requirement for outlier exclusion in international sensitivity index calibration of thromboplastin. J Thromb Haemost 5:1975–1976

    Article  PubMed  Google Scholar 

  54. van den Besselar AMHP, Breukink E, Koorengevel MC (2010) Phosphatidylglycerol and daptomycin synergistically inhibit tissue factor-induced coagulation in the prothrombin time test. J Thromb Haemost 8:1429–1430

    Article  Google Scholar 

  55. Webster PS, Oleson FB, Paterson DL et al (2008) Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/internationalized normalized ratio results. Blood Coagul Fibrinolysis 19:32–38

    Article  CAS  PubMed  Google Scholar 

  56. Yamada T, Kato R, Oda K et al (2016) False prolongation of prothrombin time in the presence of a high blood concentration of daptomycin. Basic Clin Pharmacol Toxicol 119:353–359

    Article  CAS  PubMed  Google Scholar 

  57. Hartmann B, Maus S, Keller F et al (2011) Thrombocytopenia, INR prolongation, and fall in fibrinogen under daptomycin. J Chemother 23:183–184

    Article  CAS  PubMed  Google Scholar 

  58. Cubeddu LX (2003) QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 10:452–457

    Article  PubMed  Google Scholar 

  59. Barriere SL, Goldberg MR, Janc JW et al (2011) Effects of telavancin on coagulation test results. Int J Clin Pract 65:784–789

    Article  CAS  PubMed  Google Scholar 

  60. Gosselin R, Dager W, Roberts A (2011) Effect of telavancin (Vibativ) on routine coagulation test results. Am J Clin Pathol 136:848–854

    Article  CAS  PubMed  Google Scholar 

  61. Ero MP, Harvey NR, Harbert JL (2014) Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis 38:235–240

    Article  CAS  PubMed  Google Scholar 

  62. Amanatullah DF, Lopez MJ, Gosselin RC et al (2013) Artificial elevation of prothrombin time by telavancin. Clin Orthop Relat Res 471:332–335

    Article  PubMed  Google Scholar 

  63. Belley A, Robson R, Francis JL et al (2017) Effects of oritavancin on coagulation tests in the clinical laboratory. AACA 61:e01968–e01916

    CAS  Google Scholar 

  64. Baxter K (2010) Stockley’s drug interactions [online]. Pharmaceutical Press, London. Available at: www.medicinescomplete.com. Date accessed: 28 July 2010

  65. Arizona CERT (2017) Available at: www.qtdrugs.org. Date accessed: 24 Jan 2017

  66. Micromedex (2016). Available at: www.thomsonhc.com/hcs/librarian. Date accessed: 28 Dec 2016

Download references

Author information

Authors and Affiliations

  1. Regions Hospital, Department of Pharmacy, St. Paul, MN, USA

    Mary A. Ullman

  2. University of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, MN, USA

    John C. Rotschafer

Authors
  1. Mary A. Ullman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John C. Rotschafer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John C. Rotschafer .

Editor information

Editors and Affiliations

  1. College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA

    Manjunath P. Pai

  2. Department of Pharmaceutical Sciences, Skagg School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado, USA

    Jennifer J. Kiser

  3. Division of Pharmacy Practice and Administration, UMKC School of Pharmacy at MSU, Springfield, Missouri, USA

    Paul O. Gubbins

  4. College of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, Illinois, USA

    Keith A. Rodvold

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ullman, M.A., Rotschafer, J.C. (2018). Glycopeptides, Lipopeptides, and Lipoglycopeptides. In: Pai, M., Kiser, J., Gubbins, P., Rodvold, K. (eds) Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Infectious Disease. Humana Press, Cham. https://doi.org/10.1007/978-3-319-72416-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72416-4_4

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-72415-7

  • Online ISBN: 978-3-319-72416-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation